For the pharmaceutical industry, the proposed tax reform might be spelled this way: G-I-F-T.
After years of grousing about the tax code, drug makers stand to benefit substantially from the changes the Trump administration is seeking. In fact, to a great extent, the plan that the White House is proposing appears to check off a few key items on an industry wish list, according to one tax expert.
About the Author Reprints
